KENNESAW, Ga., March 19, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the signing of a global distribution agreement with Systagenix, whereby Systagenix will co-market EpiFix®. The MiMedx branded and proprietary biologic implant specifically processed from amniotic tissue, EpiFix® offers a wide variety of wound healing and wound care options.
Based in Gatwick, United Kingdom, Systagenix will commence its launch of EpiFix® during March 2012. As part of its global distribution agreement with MiMedx, Systagenix will initially conduct the first phase of its global launch of EpiFix® throughout the United States, with launches in other countries to follow pending appropriate regulatory approvals. MiMedx will also continue to sell EpiFix® through its existing distributor channels.
EpiFix® is another of the MiMedx tissue offerings uniquely processed through the Company's proprietary Purion(SM) Process to optimize wound care and ease of use. EpiFix® is an allograft from amniotic tissue which has been shown to promote the healing of soft tissues. The Purion(SM) Process retains the amniotic growth factors inherent in and unique to placental tissue which promotes cellular ingrowth and enhanced healing.
EpiFix® has unique and differentiating characteristics such as its 5-year shelf life and stability at room temperature, its ease of handling and manipulation by physicians, its disinfection process that protects any compromise of the amniotic membrane delicate structure and its clinical history and testing results confirming that EpiFix® retains several growth factors associated with promoting cell proliferation.Parker H. "Pete" Petit, Chairman and CEO, said, "We are very pleased with this opportunity to partner with Systagenix. The combined efforts of the Systagenix sales and marketing team with our existing sales, marketing and distribution channels will allow us to more effectively reach the advanced wound care therapies segment of the market."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts